ERBB2 and breast cancer: The most frequent subtype of BC, accounting for 70% of cases, is luminal BC, which is dependent on estrogenic transcriptional programs and is usually identified in the clinical setting as the subgroup of hormone receptor (HR)-positive tumors with an absence of HER2 amplification (HER2 negative) [2].